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1  | INTRODUC TION
Global livestock systems are experiencing profound changes as a 
result of anthropogenic pressures including the growing human pop-
ulation, consumption patterns and environmental issues (Herrero 
& Thornton, 2013). Healthy animals are critical for sustainable live-
stock farming, and, as systems evolve, there is a growing need for 
veterinary services, improved disease surveillance and control tools 
to understand and manage animal and zoonotic disease dynamics 
(Perry, Grace, & Sones, 2013).
Livestock health is an integral component of the challenges fac-
ing global human communities in the 21st century. Approximately 
60% of all human infectious diseases and 75% of emerging human 
infections are caused by pathogens of (wild) animal origin. Hence, 
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Abstract
The Strategic Alliance for Research into Infectious Diseases of Animals and Zoonoses 
(STAR-IDAZ) International Research Consortium (IRC) coordinates global animal 
health research to accelerate delivery of disease control tools and strategies. With 
this vision, STAR-IDAZ IRC has constructed four generic research roadmaps for the 
development of candidate vaccines, diagnostic tests, therapeutics and control strate-
gies for animal diseases. The roadmaps for vaccines, diagnostic tests and therapeu-
tics lead towards a desired target product profile (TPP). These interactive roadmaps 
describe the building blocks and for each the key research questions, dependencies, 
challenges and possible solution routes to identify the basic research needed for 
translation to the TPP. The control strategies roadmap encompasses the vaccine, di-
agnostic tests, and therapeutic roadmaps within a wider framework focusing on the 
inter-dependence of multiple tools and knowledge to control diseases for the benefit 
of animal and human health. The roadmaps are now being completed for specific 
diseases and complemented by state-of-the-art information on relevant projects and 
publications to ensure that the necessary research gaps are addressed for selected 
priority diseases.
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the wildlife–livestock–human interfaces are important drivers for 
emergence and transmission of zoonotic diseases (Taylor, Latham, 
& Woolhouse, 2001). Control of animal diseases can therefore 
have wide-ranging health and socio-economic impacts on humans 
such as cost-effective provision of food, reductions in water-borne 
diseases and financial survival of rural populations. The handling 
and consumption of uncooked contaminated livestock products 
compromise food safety and pose potential risks of zoonotic dis-
ease transmission (van den Brom, de Jong, van Engelen, Heuvelink, 
& Vellema, 2020). Antimicrobial resistance (AMR) in humans is in-
ter-linked with AMR in farm animals and in the wider environment 
(Woolhouse, Ward, van Bunnik, & Farrar, 2015). Finally, control 
of infectious diseases in ruminant livestock can reduce methane 
emissions by as much as 33% thereby mitigating against climate 
change (Fox, Smith, Houdijk, Athanasiadou, & Hutchings, 2018). 
These grand challenges call for solutions requiring co-ordinated, 
cross-disciplinary approaches involving multiple stakeholders, 
that needs to cooperate for the collective good (http://www.
onehe althg lobal.net/). The global Strategic Alliance for Research 
into Infectious Diseases of Animals and Zoonoses (STAR-IDAZ) 
International Research Consortium (IRC) aims to coordinate global 
research for the development of new and improved animal health 
strategies for priority diseases/infections/issues. STAR-IDAZ IRC 
currently has 28 partners from 19 countries and is linked to the 
wider STAR-IDAZ network of over 40 countries. It is governed 
by an Executive Committee, advised by a Scientific Committee, 
and is supported by the Secretariat for the International Research 
Consortium on Animal Health (SIRCAH) which coordinates STAR-
IDAZ IRC activities. It also has a number of Working Groups as-
signed to priority diseases or topics. Details of the structure, aim 
and objectives of STAR-IDAZ IRC can be found on the website 
(https://www.star-idaz.net/).
Here, we describe the construction of four generic STAR-IDAZ 
IRC roadmaps for the development of candidate vaccines, diagnostic 
tests, therapeutics and disease control strategies. We explain how 
these generic roadmaps can be applied to develop disease-specific 
roadmaps that can be ultimately translated into the development of 
novel tools and strategies for disease control.
2  | CONSTRUC TION OF THE GENERIC 
STAR-IDA Z IRC ROADMAPS
The four generic roadmaps were constructed by considering the de-
sired endpoint, which could be a target product profile (TPP) or a con-
trol strategy, and working back through the steps that are essential 
for reaching that endpoint. This creates a continuous pipeline that 
encompasses basic and translational scientific research to deliver the 
goal. Each step on the roadmaps is shown as a distinct node. Each 
node defines a criterion/theme that is essential for progressing to-
wards the final goal. The generic roadmaps have been designed to be 
broadly applicable to the STAR-IDAZ IRC priority diseases to be fit for 
purpose. There are two exceptions to this which are described below.
To avoid the roadmaps becoming overly complicated, criteria/
themes were only assigned to nodes if they constituted a major 
barrier to progression to the final goal. Certain nodes have sub-
themes but only where these are inter-related to each other and the 
overarching theme. Each node is populated with five ‘Lead’ areas 
that highlight the knowns and unknowns for the issue in question. 
These are as follows: (1) research question; (2) challenge; (3) solution 
routes; (4) dependency notes; and (5) state of the art. Each Lead has 
an over-arching question and/or statement of intent with supporting 
information that is designed to focus research efforts (Figure 1).
The STAR-IDAZ IRC generic roadmaps can be accessed here: 
https://roadm aps-public.star-idaz.net/#/home. The roadmaps are 
interactive and by placing the cursor above a given node, the direc-
tion of travel of nodes that feed into that node will appear. The four 
generic roadmaps are described in the subsections below.
2.1 | Roadmap for the development of 
candidate vaccines
Vaccination is a well-established and sustainable strategy for the 
prevention and control of infectious diseases and the enormous con-
tribution that vaccines have made to societal health cannot be un-
derestimated. Indeed, they have been described as ‘an achievement 
of civilization, a human right, our health for the future’ (Rappuoli, 
F I G U R E  1   The five Lead areas 
listed under each node on the generic 
roadmaps. Each Lead has an overarching 
question and/or contains information on 
the current state of knowledge with the 
collective aim of focusing research efforts 
towards the desired goal.
1. Research question: What are we trying to achieve and why? What is 
the problem we are trying to solve?
2. Challenge: What are the scientific and technological 
challenges (knowledge gaps needing to be 
addressed)?
3. Solution routes: What approaches could/should be taken to 
address the research question?
4. Dependency notes: What else need to be done before we can solve 
this need?
5. State-of-the-art: Existing knowledge including successes and 
failures
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Santoni, & Mantovani, 2019). Early vaccines were developed ‘em-
pirically’ rather than ‘rationally’, relying on growth of the organism 
to produce the vaccine antigen (De Gregorio & Rappuoli, 2014). In 
learning from past success, we must adapt, develop, exploit and 
apply technological advances to new approaches to vaccinology 
to deal with evolving threats to global health (Andreano, D'Oro, 
Rappuoli, & Finco, 2019). There are many criteria that a successful 
vaccine must meet. While safety and efficacy are foremost, vaccines 
need to be stable, cost-effective and easy to deliver to the target 
population. These criteria need to be considered in the TPP and the 
earlier in the research pipeline that these criteria are identified, the 
greater the likelihood of developing a vaccine that meets the tar-
geted stakeholder needs.
While there are different types of vaccines (attenuated organ-
isms, inactivated organisms, genetic, subunit and vectored), there 
are a number of common criteria that need to be considered for all. 
These are safety, delivery route, delivery platform and efficacy in a 
challenge model (Figure 2). These four criteria are examples of in-
ter-related sub-themes within a common theme as described above. 
The choice of vaccine type depends on a number of factors that are 
not common to all. Thus, the attenuated vaccine nodes are linked 
to identification of virulence factors node but are not to adjuvants 
whereas the opposite is true for subunit vaccines. This reflects the 
relative co-dependencies of these nodes. Likewise, knowledge of 
protective antigens has different dependencies for different vaccine 
types. A notable advantage of veterinary vaccine research compared 
to human is the experimental challenge model to evaluate efficacy. 
In veterinary species, this is usually conducted in the target species 
which avoids the translational step from a biomedical model into 
the target species. This provides opportunities to study immune 
responses to both vaccination and challenge in the natural host 
(Entrican, Wattegedera, & Griffiths, 2015).
2.2 | Roadmap for the development of 
diagnostic tests
The reliable identification of infected animals is a fundamental com-
ponent of effective disease control strategies. It also underpins many 
government policies for the movement and trade of animals and 
animal products (Holm, Hill, Farsang, & Jungback, 2019). Sensitive 
and specific diagnostic tests not only underpin the generation of 
reliable epidemiological data and the development of targeted con-
trol approaches, they are also a major driver for investment in the 
development of new vaccines and therapeutics. Effective diagnostic 
tests need to be accurate and internationally standardized to ensure 
consistent results in different settings, and there is a recognized 
need for international harmonization of diagnostic testing for live-
stock diseases (Holm et al., 2019). The OIE Manual of Diagnostic 
Tests and Vaccines for Terrestrial Animals (OIE, 2019a) and Manual 
F I G U R E  2   Roadmap for the development of candidate vaccines. The interactive vaccine development roadmap can be found at https://
roadm aps-public.star-idaz.net/#/34wCF
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of Diagnostic Tests for Aquatic Animals (OIE, 2019b) provide inter-
national standards for diagnostics methods, which are essential for 
ensuring the control of animal diseases, and the safe trade of animals 
and their products, at a global level.
The development of new diagnostic tests should take into ac-
count their application to ensure that they are fit for purpose with a 
defined TPP. As for the vaccine roadmap, this is the starting point of 
the STAR-IDAZ IRC diagnostic tests roadmap and can be derived from 
the five Lead areas (Figure 3). Diagnostic tests can indicate current 
and past infection through a combination of pathogen detection and 
measurement of host immune responses (antigen-specific humoral or 
cellular immunity). The relative importance of these tests depends 
on the disease in question and their development relies on different 
research approaches. Consequently, within the roadmap, ‘organism 
detection’ and ‘host-pathogen interactions’ are two distinct nodes 
that link back to the original diagnostic sample. Both nodes have sub-
themes to encapsulate different inter-related elements. Although 
distinct, these themes are not absolutely mutually exclusive; hence, 
they both link to the node on identification of biomarkers. The impor-
tance of this comes to the fore when considering the many endemic 
diseases of livestock that are subclinical in nature. Infection with such 
pathogens can result in ‘carrier status’ animals that do not have overt 
disease but can still transmit infection to other animals and also po-
tentially to humans depending on the pathogen in question and cause 
production losses in livestock (Tomley & Shirley, 2009).
Knowledge of the host immune response and of biomarkers is 
also important for development of concerted disease control strat-
egies involving diagnosis and vaccination. The specification of the 
diagnostic test and the vaccine can influence vaccine deployment in 
situations where disease surveillance and management policies rely 
on the ability of diagnostic tests to discriminate between infected 
and vaccinated animals (DIVA). In such cases, the information in the 
‘dependencies’ tab needs to be taken into consideration.
2.3 | Roadmap for the development of therapeutics
While ‘prevention is better than cure’ is a highly desirable goal in 
disease control, it is not always easy to achieve. Depending on the 
policies for different livestock diseases, this can mean culling or 
treatment. Antibiotics and antiparasitics are common therapeutics 
for control of livestock diseases, and both are used extensively in 
animal production systems. However, their deployment needs to 
be carefully managed to maximize impact while minimizing poten-
tial adverse effects in animals, humans and on the environment 
(Vercruysse et al., 2018; Woolhouse et al., 2015). Despite the emer-
gence of AMR and the development of new vaccines that can help 
to reduce the use of antibiotics (Hoelzer et al., 2018), new therapeu-
tic options (e.g. antimicrobial peptides, phages and immunostimu-
lants) will be needed to preserve animal health and welfare (Seal, 
Lillehoj, Donovan, & Gay, 2013). The control of parasitic helminths 
is heavily reliant on therapeutics due to the difficulties in develop-
ing effective prophylactic vaccines. However, anthelminthic resist-
ance is making parasite control increasingly more difficult, hence the 
need to develop new treatments and control strategies (Vercruysse 
et al., 2018). The STAR-IDAZ IRC roadmap for developing new thera-
peutics is shown in Figure 4.
Once again, the starting point for development of a novel 
therapeutic is the TPP and it is identified within the five Leads 
under the ‘therapeutic’ node. Practical steps in the process involve 
chemistry, risk assessment methodologies and clinical testing. 
In turn, these are dependent on more basic knowledge of host–
pathogen interactions and mode of action that allow screening 
of compound libraries for identification of potential target com-
pounds for evaluation in animal models for pharmacokinetics and 
efficacy (Figure 4).
2.4 | Roadmap for the development of disease 
control strategies
The roadmaps for candidate vaccines, diagnostics and therapeutics 
have all been designed with a TPP in mind (Figures 2-4). However, 
the roadmap for development of disease control strategies has been 
constructed to provide an over-arching framework that integrates 
the multiple components of successful disease control strategies. 
This includes vaccines, diagnostic tests and therapeutics that all feed 
into the ‘control tools’ node either directly or indirectly. Thus, the 
F I G U R E  3   Roadmap for the development of diagnostic tests. The interactive diagnostic test development roadmap can be found at 
https://roadm aps-public.star-idaz.net/#/yuBvI
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three other generic roadmaps can be directly accessed via the dis-
ease control roadmap by clicking on their ascribed nodes (Figure 5).
The roadmap incorporates socio-economic and environmental 
(including farming system) aspects of disease control. The uptake and 
F I G U R E  4   Roadmap for the development of therapeutics. The interactive therapeutic development roadmap can be found at https://
roadm aps-public.star-idaz.net/#/bUDor
F I G U R E  5   Roadmap for the development of control strategies. The outcome of the control strategies roadmap (blue) also incorporates 
the other three generic roadmaps (green). The interactive control strategies roadmap can be found at https://roadm aps-public.star-idaz.
net/#/XkjSS
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implementation of control strategies are dependent on the socio-eco-
nomic factors; hence, these are closely linked on the roadmap and 
need to be considered at an early stage of development (Charlier & 
Barkema, 2018). The roadmap takes into account disease surveillance, 
epidemiology and modelling that are linked back to the basic science 
that generates knowledge on infection status, host range, pathogen 
genome and also host genetics. Depending on the disease in question 
and the tools available (or under development), control strategies also 
include contact tracing of animals, segregation of infected animals and 
culling. As for the previous roadmaps, the basic scientific research will 
be driven by an awareness of the ultimate translational goal, which in 
this case is a practical and effective disease control strategy.
3  | APPLIC ATION OF THE GENERIC 
ROADMAPS TO THE STAR-IDA Z IRC 
PRIORIT Y DISE A SES
In addition to the generic roadmaps described above, the STAR-IDAZ 
IRC has been developing roadmaps for its priority diseases. These 
are at different stages of development, reflected by their relative 
current representation within the generic roadmaps. The most fully 
developed disease roadmaps today are those for foot-and-mouth 
disease (FMD), African swine fever (ASF), porcine reproductive and 
respiratory syndrome (PRRS), bovine tuberculosis (bTB), helminth 
infections and brucellosis (https://roadm aps-public.star-idaz.net/#/
home). The construction of the disease roadmaps is informed by the 
gap analyses that are conducted by the various STAR-IDAZ IRC WGs 
(https://www.star-idaz.net/repor ts/gap-analysis). Several of these 
diseases are already a focus of co-ordinated international research 
alliances such as FMD (Global Foot-and-Mouth Research Alliance 
[GARA]), ASF (Global African Swine Fever Research Alliance [GARA)], 
bTB (Global Research Alliance for Bovine Tuberculosis [GrabTB]) and 
helminths (Livestock Helminth Research Alliance [LiHRA]). These alli-
ances have been heavily involved in the STAR-IDAZ IRC disease-spe-
cific roadmaps. Building on the success of this approach, STAR-IDAZ 
IRC envisages to support the creation of new alliances to perform 
gaps analyses for the other priority diseases as listed on the consor-
tium website (https://www.star-idaz.net/prior ity-topic/).
The gap analyses inform on the research priorities for the dif-
ferent diseases. For example, improved detection/identification 
tools are required for FMD, ASF and helminths; hence, these can 
be found within the generic diagnostic tests roadmap whereas new/
improved vaccines are required for FMD, bTB, ASF, PRRS, helminths 
and brucellosis and these can all be found within the generic vaccine 
roadmap. However, FMD, ASF and helminths (but not the others) 
appear in the generic diagnostic roadmap since improved detection/
identification tools are specifically required for these diseases. Only 
helminths appear under the therapeutic roadmap as novel thera-
peutics are not desired control options for the other diseases. These 
differences are encapsulated with the generic control strategies 
roadmap where the relative importance of the various control tools 
for a specific disease can be evaluated together.
Avoidance of unnecessary duplication of effort in research is 
dependent on knowledge of existing projects. To this end, funded 
projects (where known) are listed within the nodes of the roadmaps. 
A database of almost 200 European-funded animal health and wel-
fare projects that are currently running or have ended in the past 
two years can be found here: https://datab ase.scar-cwg-ahw.org/. 
Details of these research projects are either supplied by the member 
organizations in the STAR-IDAZ IRC and are added to the database 
by SIRCAH, or are provided by researchers who have been approved 
to enter their project details themselves. Researchers are invited to 
‘Sign up’ on the Roadmaps page and can then be approved to begin 
adding their project data.
4  | DISCUSSION
The overall objective of the STAR-IDAZ IRC is to coordinate re-
search at the international level to contribute to new and improved 
animal health strategies for a number of priority diseases/infec-
tions/issues and deliver candidate vaccines, diagnostic tests and 
therapeutics. The four generic roadmaps described here are de-
signed to focus research efforts on the key gaps in knowledge 
and capability that need to be addressed to deliver control tools 
or strategies for any given disease in an animal host. Gap analy-
sis in animal disease control is regularly performed by various 
organizations or initiatives such as the DISCONTOOLS database 
where the availability of animal disease control tools and the as-
sociated gaps and research needs are mapped and updated for 
over 50 infectious animal diseases (O'Brien, Scudamore, Charlier, 
& Delavergne, 2017).
The generic roadmaps described here have evolved as a process 
of STAR-IDAZ activities. Through global coordination, STAR-IDAZ 
IRC decided to build further on existing gap analyses by structuring 
them into research roadmaps. The STAR-IDAZ IRC research road-
maps originated from the idea that by structuring gap analyses of 
disease control in a logical order, similar to critical path analysis, the 
key research bottlenecks can be better identified. Moreover, during 
the construction of the roadmaps and discussions with various dis-
ease experts, it became clear that the development of a vaccine/
diagnostic/therapeutic/control strategy often requires similar re-
search approaches, independent of the infectious disease consid-
ered. This allowed for the generic roadmap concept. The generic 
roadmaps are used as the backbone to collect and structure dis-
ease-specific research needs. Disease-specificity can also be encap-
sulated by leaving non-relevant nodes in the roadmap blank, which 
will remain shaded in the interactive webtool. At the core of STAR-
IDAZ IRC research roadmaps is the concept that by mapping ongoing 
research efforts over the roadmaps, unfunded but needed areas of 
research may become easily identifiable.
The development of tools that systematically identify knowl-
edge and capability gaps are beneficial to both researchers and 
funders alike as they support the co-ordinated prioritization of 
research funding. This approach is exemplified by the United 
     |  7ENTRICAN ET Al.
Kingdom Department of Health and Social Care (DHSC) Vaccine 
Network (UKVN) which has adopted a systematic approach to 
prioritize vaccinology research into animal pathogens with human 
epidemic potential (Noad et al., 2019). The approach took into ac-
count the stage of vaccine development for each pathogen which 
could then be mapped to a pipeline using an interactive tool 
that identifies bottlenecks in vaccine development with a focus 
on the TPP. The underlying principle is that the identification of 
these rate-limiting bottlenecks allows funders to take corrective 
action by directing their strategies accordingly (Drury, Jolliffe, 
& Mukhopadhyay, 2019). The DHSC UKVN funding is primarily 
(but not exclusively) focussed on human vaccine development as 
there is also recognition that disease control in the animal host 
will reduce transmission of infection to humans. Consequently, 
DHSC UKVN has therefore developed an equivalent pipeline tool 
for veterinary vaccine development (Francis, 2020). This tool 
shares conceptual similarities with the STAR-IDAZ IRC vaccine 
roadmap, but differs by incorporating regulatory processes in the 
pipeline process. The STAR-IDAZ IRC generic roadmaps address 
fundamental and translational research priorities for animal dis-
eases and consider not only vaccine development, but also the 
development of accompanying diagnostics, therapeutics and key 
scientific information that could lead to more effective control 
strategies.
In conclusion, the four generic STAR-IDAZ IRC roadmaps de-
scribed here are designed to highlight gaps in knowledge and capa-
bility that then focus research activities that address those gaps and 
advance the control of infectious diseases of animals and zoonoses. 
These roadmaps should therefore be used by research funders and 
donors in the development of research calls, as well as by research-
ers at an early stage of preparing funding proposals to speed up the 
delivery of innovative control tools against priority animal diseases.
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